Teva Pharmaceutical Industries and Active Biotech have announced that both companies remain committed to the Nerventra(laquinimod)clinical development program for multiple sclerosis(MS)following the announcement of a negative opinion for ...
Tags: Medicine, clinical studies, Nerventra
Teva Pharmaceutical has licensed rights to commercialize glatiramer acetate to Takeda Pharmaceutical in Japan as part of their agreement signed earlier in 2013. Currently both the firms are working on additional agreements for ...
Tags: Teva Licenses, Medicine
The US Food and Drug Administration (FDA) has granted orphan drug status for Teva Pharmaceutical's Treanda injection through October 2015 for indolent B-cell non-Hodgkin lymphoma (iNHL) that has progressed during or within six months of ...
Antares Pharma, a provider of self-injection drug delivery technology, has received a US Patent, entitled 'Prefilled Syringe Jet Injector', which will help in protecting its auto injector technology and product pipeline including the VIBEX ...
A multiple-sclerosis drug that was at the center of Sanofi SA's SAN.FR +1.12% $20 billion takeover battle for Genzyme Corp. three years ago was approved for sale in Europe on Tuesday, the drug's first regulatory approval world-wide. The ...
Cancer Research Technology (CRT), Cancer Research UK's technology development arm, has signed a multi-project alliance agreement with Teva Pharmaceutical Industries (TEVA) to research and develop new cancer drugs, which will help in ...
Champions Oncology (Champions), a developer of advanced technology solutions and services to personalize the development and use of oncology drugs, has signed a new discovery and drug development partnership with Teva Pharmaceutical ...
Tags: Champions Oncology
One of the world's top-selling drugs—GlaxoSmithKline PLC's $8-billion-a-year asthma treatment Advair—became more vulnerable to generic competition after the U.S. Food and Drug Administration issued guidance on the regulatory ...
The European Commission has granted marketing authorization for Teva Pharmaceutical Industries' Lonquex (lipegfilgrastim) to commercialize in all twenty eight countries of the European Union plus Norway, Iceland and Liechtenstein. ...
Teva Pharmaceutical Industries has introduced generic version of Pfizer's Viagra (sildenafil) in Germany, UK, Italy, the Netherlands, Switzerland, Ireland, Austria, Belgium and Denmark following patent expiry. Offered through the ...
Tags: Pfizer's Viagra, Viagra
Teva Pharmaceutical Industries has signed an agreement to purchase pharmaceutical and drug delivery company, MicroDose Therapeutx, to strengthen its respiratory franchise. The deal involves acquisition of all of MicroDose's outstanding ...
The USFDA has accepted Teva Pharmaceutical Industries' supplemental new drug application (sNDA) for reviewing Copaxone (glatiramer acetate injection) 40mg/1mL. Indicated for patients with relapsing-remitting multiple sclerosis (RRMS), the ...
Tags: Drug Application, Medicine
Teva Pharmaceutical Industries has reported a net income attributable to the company of $630m or $0.74 per share for the first quarter ended 31 March 2013 compared to $859m or $0.97 per share for the first quarter ended 31 March 2012. Net ...
Tags: Teva, Pharmaceutical
Teva has established Global Specialty Medicines group as part of its strategic plan to optimize commercialization. The company has named Dr. Rob Koremans as the president and CEO of Global Specialty Medicines. Koremans will report to ...
Tags: Teva, Medicines Group
Teva Pharmaceutical and Xenon Pharmaceuticals have announced the FDA orphan drug designation for analgesic XEN402 being developed to treat pain associated with erythromelalgia (EM). The novel chemical entity XEN402 is designed to inhibit ...
Tags: Pharmaceutical, FDA, Orphan Drug